Mangalam Drugs and Organics Ltd
Incorporated in 1977, Mangalam Drugs
& Organics Ltd manufactures Active Pharmaceutical Ingredients and
Intermediates[1]
- Market Cap ₹ 122 Cr.
- Current Price ₹ 77.0
- High / Low ₹ 145 / 70.1
- Stock P/E 12.0
- Book Value ₹ 93.5
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.82 times its book value
Cons
- Company has low interest coverage ratio.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | TTM | |
|---|---|---|
| 369 | 347 | |
| 351 | 310 | |
| Operating Profit | 17 | 37 |
| OPM % | 5% | 11% |
| 0 | 0 | |
| Interest | 14 | 15 |
| Depreciation | 15 | 16 |
| Profit before tax | -11 | 7 |
| Tax % | -18% | |
| -9 | 10 | |
| EPS in Rs | -5.73 | 6.44 |
| Dividend Payout % | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 1% |
| 3 Years: | -12% |
| 1 Year: | -24% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Sep 2024 | |
|---|---|---|
| Equity Capital | 16 | 16 |
| Reserves | 120 | 132 |
| 106 | 83 | |
| 92 | 133 | |
| Total Liabilities | 334 | 364 |
| 148 | 161 | |
| CWIP | 8 | 0 |
| Investments | 0 | 0 |
| 178 | 203 | |
| Total Assets | 334 | 364 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | |
|---|---|
| 4 | |
| -12 | |
| 5 | |
| Net Cash Flow | -3 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | |
|---|---|
| Debtor Days | 28 |
| Inventory Days | 185 |
| Days Payable | 99 |
| Cash Conversion Cycle | 113 |
| Working Capital Days | 90 |
| ROCE % |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Management
11 Apr - Appointment of CFO and auditors for FY 2025-26.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Friday, 11Th April, 2025 At 2:00 P.M.
11 Apr - Appointment of CFO and auditors for FY 2025-26.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
9 Apr - Certificate under Regulation 74(5) for Q1 2025.
-
Regulatory Update As Per Regulation 31(4) Of Substantial Acquisition Of Shares And Takeover Regulations, 2011
7 Apr - Declaration of no substantial acquisition of shares.
-
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 11Th April, 2025 To Approve Appointment Of Chief Financial Officer Of The Company W.E.F. 11Th April, 2025
4 Apr - Board meeting scheduled for CFO appointment on April 11, 2025.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from nse
-
Financial Year 2012
from bse
Business Overview:[1]
Company manufactures bulk drugs, organic and inorganic chemicals. It is among the few companies which are World Health Organization -approved Indian companies to be associated with the William J Clinton Foundation for manufacture of anti-malarial drugs. Company supplies artemisinin-based bulk drugs to pharmaceutical companies, for manufacturing anti-malarial formulations